Wave Life Scienc Stock Price, News & Analysis

Wave Life Sciences (Nasdaq: WVE) announced that management will participate in two investor conferences in November 2025.

Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno, MD, MBA, President and CEO, will speak in an analyst-led fireside chat on Tuesday, November 11, 2025 at 10:00 a.m. ET.

Jefferies London Healthcare Conference — Dr. Bolno will join an analyst-led fireside chat on Thursday, November 20, 2025 at 8:30 a.m. GMT / 3:30 a.m. ET and participate in an Anti-Obesity Panel at 9:00 a.m. GMT / 4:00 a.m. ET. Live webcasts and limited-time replays are available via the company’s Investors "Investor Events" page.

Wave Life Sciences (NASDAQ: WVE) will present preclinical data for WVE-007 (INHBE GalNAc-siRNA) at ObesityWeek® on November 6, 2025, showing a potential approach to drive fat loss while preserving muscle with once- or twice-yearly dosing.

Key preclinical findings: single-dose weight loss in DIO mice, visceral adipose reductions, adipocyte shrinkage, fewer pro-inflammatory macrophages (up to 80%), reduced fibrosis (58%), and doubled weight loss when combined with semaglutide. Early clinical INLIGHT results show dose-dependent Activin E decreases of 56–85% at Day 29 and durable reductions through six months; WVE-007 was reported as safe and well tolerated to date.

Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 10, 2025 to review third quarter 2025 financial results and provide business updates.

Investors and analysts can access the live event via the company’s Investor Events page and analysts may join the Q&A by phone using the audio-conferencing link. An archived webcast will be posted on the Wave Life Sciences website after the live presentation.

Wave Life Sciences (Nasdaq: WVE) corrected its Oct 29, 2025 release to report INLIGHT trial target engagement for WVE-007 (GalNAc-siRNA) in obesity.

Key clinical facts: single doses produced dose-dependent mean Activin E reductions of 85% (400 mg), 75% (240 mg), and 56% (75 mg) at day 29 (p<0.0001). Cohort 1 reductions were sustained through six months, supporting once- or twice-yearly dosing. WVE-007 is reported as safe and well tolerated to date. Multiple follow-up data milestones are expected between 4Q2025 and 2Q2026.

Additional updates: WVE-006 showed total AAT to 13 µM with 64% wild-type M-AAT after treatment and an individual >20 µM; WVE-008 (PNPLA3) CTA planned in 2026; company presented preclinical dual edit+silence modality.

Wave Life Sciences (Nasdaq: WVE) reported dose-dependent, highly significant Activin E reductions from its INLIGHT trial of WVE-007 for obesity: 85% (400 mg), 75% (240 mg) and 56% (75 mg) at day 29 post single dose, with Cohort 1 reductions sustained through six months. WVE-007 was described as generally safe and well tolerated to date and an independent committee supported expansion to a 600 mg cohort. Multiple INLIGHT body-composition and weight updates are planned starting 4Q 2025. Wave also announced WVE-008 (PNPLA3 RNA editing) with a CTA expected in 2026, and highlighted pipeline advances in RNA editing and combined edit/silence oligonucleotide constructs.

Wave Life Sciences (NASDAQ: WVE), a clinical-stage biotechnology company specializing in RNA medicines, has announced its upcoming Virtual Research Day scheduled for October 29, 2025, at 10:00 a.m. ET.

The company's management team will also participate in several investor conferences in September and October 2025, including the Bernstein Healthcare Forum, Stifel Virtual Cardiometabolic Forum, and Chardan's Genetic Medicines Conference. Live webcasts will be available through Wave's investor relations website, with replays accessible for a limited time after each event.

Wave Life Sciences (NASDAQ:WVE) announced positive data from their ongoing Phase 1b/2a RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD). The study achieved significant clinical milestones, demonstrating durable production of serum AAT protein at therapeutic levels following 200 mg doses (11.9 µM total AAT, 7.2 µM M-AAT).

The trial marked the first-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during an acute phase response, reaching 20.6 µM total AAT. A single 400 mg dose achieved 12.8 µM total AAT, with an ongoing multidose cohort showing potential for further increases. The data supports monthly or less frequent subcutaneous dosing, with 400 mg monthly multidose cohort data expected in Q1 2026.

WVE-006, licensed to GSK, continues to demonstrate favorable safety with only mild to moderate adverse events. Wave is eligible for up to $525 million in milestones plus tiered royalties on net sales.

XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.

Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.

DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.

Wave Life Sciences (NASDAQ:WVE) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company reported a net loss of $50.5 million with cash and equivalents of $208.5 million, providing runway into 2027.

Key highlights include progress in two main programs: WVE-006 for AATD (alpha-1 antitrypsin deficiency), with multi-dosing complete in first cohort (200mg) and single dosing complete in second cohort (400mg), and WVE-007 for obesity, where dosing is complete in the expanded Cohort 2. The company expects multiple data readouts in H2 2025, including RestorAATion-2 trial data in Q3 2025 and INLIGHT trial data in Q4 2025.

Additionally, Wave is advancing WVE-N531 for DMD with planned NDA filing in 2026, and WVE-003 for Huntington's disease with IND submission expected in H2 2025.